Status:
UNKNOWN
Testosterone Treatment in a Patient With 17β-hydroxysteroid Dehydrogenase Type 3 Deficiency: an N-of-1 Study
Lead Sponsor:
Erasmus Medical Center
Conditions:
Disorder of Sex Development, 46,XY
Eligibility:
FEMALE
38+ years
Phase:
PHASE3
Brief Summary
A 38-year old women with a 46,XY disorder of sex development (DSD) based on a 17β-hydroxysteroid dehydrogenase type 3 deficiency (17β-HSD3) was seen at the department of Internal Medicine-Endocrinolog...
Detailed Description
A 38-year old women with a 46,XY disorder of sex development (DSD) based on a 17β-hydroxysteroid dehydrogenase type 3 deficiency (17β-HSD3) was seen at the department of Internal Medicine-Endocrinolog...
Eligibility Criteria
Inclusion
- \- N/A
Exclusion
- \- N/A
- The study is especially designed for a specific female patient. The patient is 38 years old at the moment. Since the study is especially designed for this patient, there are no formal inclusion and exclusion criteria.
Key Trial Info
Start Date :
June 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 26 2022
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT04831099
Start Date
June 1 2021
End Date
July 26 2022
Last Update
April 5 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Erasmus MC
Rotterdam, South Holland, Netherlands, 3015GD